3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Epstein-Barr Virus Infections
6
Sarcoma, Kaposi
4
Lymphoproliferative Disorders
4
Nasopharyngeal Carcinoma
3
Glioblastoma
3
Cytomegalovirus Infections
3
Multi-centric Castleman's Disease
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Acquired Immunodeficiency Syndrome
2
Stomach Neoplasms
1
Solid Tumor, Adult
1
Sarcoma
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Acyl Coenzyme A Dehydrogenase Deficiency
1
Macular dystrophy, corneal type 1
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphadenopathy
1
Leukemia
1
Immune Reconstitution Inflammatory Syndrome
1
Hodgkin Disease
1
Herpes Simplex
1
Head and Neck Neoplasms
1
HIV Infections
1
Fatigue Syndrome, Chronic
1
Fatigue
1
EBV Lymphomas
1
Interventions
Temozolomide
2
Lenalidomide
2
Granulocyte Colony-Stimulating Factor
2
Filgrastim
2
Cyclophosphamide
2
venetoclax
1
trametinib
1
toripalimab
1
tafasitamab
1
sonidegib
1
ribociclib
1
fludarabine
1
etoposide phosphate
1
camrelizumab
1
brivanib
1
apatinib
1
acalabrutinib
1
Vincristine
1
Valganciclovir
1
Thiotepa
1
Therapeutics
1
Telemedicine
1
Tamoxifen
1
Surveys and Questionnaires
1
Standard of Care
1
Rituximab
1
Radiotherapy
1
R-CHOP protocol
1
Patient Navigation
1
N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pyloric Stenosis, Hypertrophic
×
Valganciclovir
×
Clear all
NCT05011058
2025-07-28
NAVAL-1
Viracta Therapeutics, Inc.
Phase 2
Terminated
102 enrolled
28 charts